Attached files

file filename
EX-99.1 - EX-99.1 - LEAP THERAPEUTICS, INC.a18-8504_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

March 14, 2018

Date of report (Date of earliest event reported)

 


 

Leap Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-37990

 

27-4412575

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

47 Thorndike Street, Suite B1-1
Cambridge, MA
(Address of principal executive offices)

 

02141
(Zip Code)

 

Registrant’s telephone number, including area code (617) 714-0360

 

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Item 8.01              Other Events.

 

On March 14, 2018, Leap Therapeutics, Inc. (the “Company”) issued a press release announcing new clinical data from the study evaluating the Company’s anti-DKK1 monoclonal antibody, DKN-01, as a monotherapy in patients with advanced esophagogastric cancer.  The press release also announced that the first patient has been enrolled in the study evaluating DKN-01 in patients with gynecological cancers, and that the Company would be hosting two poster sessions at the AACR Annual Meeting.  The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01.     Financial Statements and Exhibits.

 

(d)           Exhibits.

 

Exhibit
Number

 

Description

99.1

 

Leap Therapeutics, Inc. Press Release dated March 14, 2018

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Leap Therapeutics, Inc.

 

 

 

 

 

Dated: March 19, 2018

By:

/s/ Douglas Onsi

 

Name:

Douglas Onsi

 

Title:

Chief Financial Officer, General

 

 

Counsel, Treasurer and Secretary

 

3